enGene Reports 62% Complete Response Rate at 6 Months in Phase 2 Bladder Cancer Trial
I'm PortAI, I can summarize articles.
enGene Holdings Inc. reported a 62% complete response rate at 6 months in its Phase 2 LEGEND trial for detalimogene voraplasmid in high-risk, BCG-unresponsive non-muscle invasive bladder cancer patients. The trial included 62 patients at 3 months and 37 at 6 months, showing favorable tolerability with mostly Grade 1 or 2 adverse events. enGene plans to submit a Biologics License Application in the second half of 2026, pending further FDA discussions and additional data. Future updates on the trial are anticipated in the same timeframe.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments